Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
about
Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETsIndividualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey.Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
P2860
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Individualized dosimetry-based ...... receptor radionuclide therapy.
@en
Individualized dosimetry-based ...... receptor radionuclide therapy.
@nl
type
label
Individualized dosimetry-based ...... receptor radionuclide therapy.
@en
Individualized dosimetry-based ...... receptor radionuclide therapy.
@nl
prefLabel
Individualized dosimetry-based ...... receptor radionuclide therapy.
@en
Individualized dosimetry-based ...... receptor radionuclide therapy.
@nl
P2093
P2860
P1476
Individualized dosimetry-based ...... receptor radionuclide therapy
@en
P2093
Alfons Verbruggen
Bert Vanbilloen
Chris Verslype
Christelle Terwinghe
Eric Van Cutsem
Felix M Mottaghy
Karin Haustermans
Kristof Baete
Luc Mortelmans
Michel Koole
P2860
P2888
P304
P356
10.1007/S00259-013-2670-X
P577
2014-03-26T00:00:00Z